Introduction {#Sec1}
============

Although the predominant driving force in breast carcinogenesis has been thought to be hormonal, cytokine production and inflammation are also being recognized as important in breast cancer development and progression \[[@CR1],[@CR2]\]. A progressive increase in activated macrophages and T cells is observed between normal breast tissue, proliferative breast disease, and breast cancer \[[@CR3],[@CR4]\]. The stimulus for the increase in inflammatory cell infiltration observed with proliferative breast disease and breast cancer is unknown but probably has varying etiologies including immunogenic gene alterations in epithelial cells \[[@CR5]\], reaction to breakdown of basement membrane components \[[@CR4]\], and for obese women excess cytokine production from dysfunctional adipocytes \[[@CR6]\].

The long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are important in generating bioactive lipid mediators important in inflammation resolution \[[@CR7]\]. As key components of phospholipid membranes and lipid rafts that serve to organize or separate molecules, these fatty acids also affect cell signaling thought to impact breast carcinogenesis \[[@CR8]-[@CR12]\]. The ability of long-chain omega-6 fatty acids to modulate inflammation and other physiologic processes is dependent on concomitant levels of the proinflammatory omega-6 arachidonic acid (AA) as well as an individual's genetic makeup governing lipid metabolism \[[@CR13]-[@CR16]\].

Interest in the use of supplementary omega-3 fatty acids to reduce risk of cancer and other chronic debilitating conditions, including cardiovascular disease and cognitive impairment, stems from several longstanding avenues of investigation: 1) an increased incidence of breast cancer and heart disease in western societies with low omega-3:omega-6 fatty acid intake ratios; 2) a very low incidence of these two conditions in populations with high marine omega-3 fatty acid intake (Japan and natives of Alaska and Greenland); 3) a dramatic increase in the incidence of breast cancer and cardiovascular disease in cohorts from low-incidence populations who migrate to western countries and/or adopt a western diet \[[@CR15],[@CR17]\]; and 4) the demonstrated importance of adequate DHA in retinal and brain development and cognitive function \[[@CR18],[@CR19]\].

Although the ideal total omega 3:omega-6 intake ratio has not been defined, a ratio approaching 1:1 or 1:2 similar to that of precivilized man is generally accepted as associated with a low incidence of diseases characterized by chronic inflammation, and therefore is desirable \[[@CR16],[@CR20]\]. By the early 1900s the omega 3:omega-6 intake ratio in the United States was estimated at 1:5, probably due to the high dietary content of corn oil products and corn-fed animals. Today, largely due to the \>1,000-fold increase in use of soybean oil in the last several decades, the dietary omega 3:omega-6 intake ratio is now 1:10 or lower \[[@CR16],[@CR21]\]. Although much of the imbalance is probably due to the increase in omega-6 consumption, it has been suggested that the most practical remedy may actually be to increase long-chain or marine omega-3 intake rather than to attempt to markedly reduce omega-6 intake \[[@CR22],[@CR23]\].

We will briefly review omega-3 and omega-6 fatty acid metabolism and function, preclinical mechanistic and prevention studies, as well as selected case--control and prospective cohort studies, and ongoing trials relevant to breast cancer prevention. Reports dealing with omega-3 fatty acids and breast cancer recurrence as well as other relevant survivorship topics including insulin resistance and obesity, cardiovascular disease and cognition will also be discussed.

What are omega-3 and omega-6 fatty acids and how do they work? {#Sec2}
==============================================================

Omega-3 and omega-6 fatty acids are a group of essential polyunsaturated fatty acids (PUFAs) that play important roles in cell membrane structure, fluidity, and cell signaling \[[@CR13]\]. The designation 3 or 6 is structural, referring to the double bond on the third or sixth carbon respectively from the methyl group \[[@CR13]\]. The most abundant dietary PUFAs are the short-chain omega-3 alpha linolenic acid (ALA) and the omega-6 linoleic acid (LA), most often ingested as plant oils. The longer chain omega-3 PUFAs EPA and DHA, commonly referred to as marine fatty acids, are most efficiently obtained from fatty cold water fish such as salmon, whereas the long-chain omega-6 fatty acid AA is obtained most efficiently from eggs, poultry, and meat \[[@CR24]-[@CR26]\] (see Figure [1](#Fig1){ref-type="fig"}). Unless EPA, DHA, and AA are directly ingested, they must be derived from ALA and LA, respectively. In general, the desaturases and elongases have a greater affinity for ALA than LA but, due to the general 10-fold higher intake of LA, generally more AA than EPA and DHA is formed \[[@CR24]\].Figure 1Dietary sources and general metabolic pathway for omega-6 and omega-3 polyunsaturated fatty acids, leading to proinflammatory and anti-inflammatory products respectively.

Whether ingested or synthesized, PUFAs are either oxidized for fuel, stored in triacylglycerol, taken up in phospholipid membranes for eventual use as substrates by cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, or used as ligands for G receptors \[[@CR26]\]. Neither LA nor ALA is readily converted to bioactive lipid products due to low uptake into phospholipid membranes. However, 5 to 10% of both LA and ALA can be converted to the longer chain PUFAs that are readily taken up in phospholipid membranes and form the substrates for conversion to bioactive lipid products by COX and LOX enzymes \[[@CR26]\] (see Figure [2](#Fig2){ref-type="fig"}).Figure 2Metabolic pathways for omega-6 and omega-3 fatty acids that result in a variety of inflammation mediators and cell function effectors. Proinflammatory (red) and anti-inflammatory or less inflammatory (green) molecules are denoted within ellipses. Other molecules are indicated that are likely to promote (red) or repress (green) neoplastic processes. Cyclooxygenase (blue) and lipoxygenase (yellow) enzymatic processes are indicated. AA, arachidonic acid; ALA, alpha linolenic acid; COX, cyclooxygenase; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HDHA, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HODE, hydroxyoctadecadienoic acid; HPETE, hydroperoxyeicosatetraenoic acid; LA, linoleic acid; LOX, lipoxygenase; LT, leukotriene; LX, lipoxin; HODE, hydroxyoctadecadienoic acid; HX, hepoxilin; MaR, maresin; PD1, protectin D1; PG, prostaglandin; Rv, resolvin; TX, thromboxane.

The omega-6 PUFA AA and its derivatives are important in a diverse set of physiologic functions including initiation and sustainment of inflammation (for example, T-cell and monocyte activation, chemotaxis), platelet aggregation, endothelial adhesion molecules, ovulation, parturition, and muscle strength. The omega-3 fatty acids EPA and DHA and their derivatives are important for retina and brain development, cognitive function, and in the production of minimally inflammatory eicosanoids as well inflammation resolving mediators termed resolvins and various tissue protectins \[[@CR20],[@CR22]\]. Although most of the bioactive lipid mediators of interest are a result of COX and LOX enzyme activity on the long-chain PUFAs EPA, DHA, and AA, 15-LOX acts on the short chain LA to form 13(S)-hydroxyoctadecadienoic acid, which is probably carcinogenic and is known to increase mammary tumor proliferation \[[@CR22]\] (see Figure [2](#Fig2){ref-type="fig"}). EPA and DHA compete with AA as substrates for COX and LOX enzymes although EPA is a poorer substrate than AA, at least for COX \[[@CR24]\].

Upon inflammatory stimulus, the enzyme phospholipase A2 releases AA from phospholipid membranes of monocytes and predominantly proinflammatory derivatives are produced (Figure [2](#Fig2){ref-type="fig"}). COX-1 and COX-2 enzymes are responsible for AA-derived prostaglandin E~2~ and other series-two prostaglandins and thromboxanes \[[@CR15],[@CR24]\]. 5-LOX, 12-LOX, and 15-LOX are responsible for generation of the series-four leukotrienes and lipoxins. Leukotrienes have chemotactic and other effects on inflammatory cells.

In general, the action of COX and LOX enzymes on the omega-3 fatty acids EPA and DHA is to produce eicosanoids with less affinity for the corresponding receptors as well as resolvins that block inflammatory cell recruitment and promote phagocytosis. The net effect if EPA and DHA are present in sufficient amounts relative to AA is anti-inflammatory or inflammation resolving. The action of COX on EPA gives rise to the series-three prostaglandins and thromboxanes, whereas actions of 5-LOX and 15-LOX ultimately produce the series-five leukotrienes and resolvins. LOX enzymes are also responsible for the DHA-derived resolvins and eventual production of neuroprotectins \[[@CR15],[@CR26]\] (see Figure [2](#Fig2){ref-type="fig"}).

Recommended and average intakes and sources of omega-3 and omega-6 fatty acids {#Sec3}
==============================================================================

No dietary reference intake has been established for EPA and DHA. Although the dietary reference intake for omega-3 ALA of 1.1 g/day for women \[[@CR27]\] is achieved by the average intake in the United States of 1.3 g/day, this is only about 1/10 of the 13 to 15 g daily intake of omega-6 LA \[[@CR28]\].

Given the general health benefits increasingly recognized for EPA and DHA, many organizations have made recommendations for direct intake of 200 to 500 mg/day EPA + DHA for adult general health in the form of fish or fish oil, krill oil, or algae oil supplements (see Table [1](#Tab1){ref-type="table"}). Average intakes of EPA and DHA combined, usually from fish or supplements, is \~100 mg/day or 0.1 to 0.2% of calories. Intake of AA is \~250 mg/day, generally from eggs, meat, and poultry \[[@CR21],[@CR25],[@CR28]\].Table 1**Recommended intakes of EPA + DHA by cohort and organizationCohortSourceDaily recommendation**General health AdultsUS Department of Agriculture≥250 mg AdultsEuropean Food Safety Agency≥250 mg AdultsWorld Health Organization:≥250 mg AdultsAcademy of Nutrition and Dietetics≥500 mg Adults without CHDAmerican Heart Association∼500 mg (fatty fish ≥ 2 times/week) AdultsInternational Society for the Study of Fatty Acids and Lipids≥500 mgPregnancy Pregnant/lactatingInternational Society for the Study of Fatty Acids and Lipids≥500 mg (≥300 mg DHA) Pregnant/lactatingEuropean Food Safety Agency≥250 mg (100 to 200 mg DHA)Heart disease and inflammatory disorders CHDAmerican Heart Association∼1 g Patients with high TGAmerican Heart Association2 to 4 gGenerally viewed as safe upper limit PopulationUS Food and Drug Administration≤3 g EPA + DHA PopulationEuropean Safety Authority5 g EPA + DHACHD, coronary heart disease; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; TG, triglyceride.

The omega-3 fatty acid intakes recommended for healthy individuals are not likely to be effective in chronic inflammatory conditions, given the level of omega-6 fatty acids in our diets \[[@CR15],[@CR23],[@CR25],[@CR28]\]. If the ratio of EPA + DHA to AA in blood or tissue is the key factor \[[@CR25],[@CR28]\], an intake of \~2 to 3 g/day combined EPA and DHA, or at least 2% of calories, is likely to be needed to result in a tissue level ratio of EPA + DHA to AA that approaches or exceeds unity. Doses generally exceeding 2 g/day combined EPA + DHA are needed to reduce prostaglandin E~2~ levels \[[@CR26]\] and doses of 3 to 3.5 g/day combined EPA + DHA are most often used in the treatment of hypertriglyceridemia or inflammatory disorders such as rheumatoid arthritis \[[@CR15],[@CR29]\]. No tolerable upper limit has been set for EPA and DHA, although the US Food and Drug Administration recognizes doses of up to 3 g/day as safe and the European Safety Union up to 5 g/day as safe \[[@CR30]\]. Side effects of fish oil supplements or EPA + DHA ethyl esters include fishy burps, dyspepsia, gas, and diarrhea \[[@CR15],[@CR29]\].

Primary sources of EPA and DHA are fish and supplements, which vary dramatically in their content. DHA is generally present in equal or higher amounts than EPA in seafood but the total amount of EPA and DHA as well as the ratios of EPA to DHA vary by supplement, and in many over-the-counter supplements EPA may be almost twice as high as DHA (see Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Fatty cold water fish such as salmon, herring, and mackerel have the highest levels of DHA and EPA, with lower levels in shellfish and many popular freshwater fish. A total of 2.4 g EPA + DHA can be obtained from a 4 oz (114 g) serving of wild Atlantic salmon but one would have to eat 8 oz (227 g) canned pink salmon, 1 lb (0.45 kg) halibut, or 5 lb (2.27 kg) shrimp to obtain the same amount (see Table [2](#Tab2){ref-type="table"}) \[[@CR31]\].Table 2**Dietary sources of EPA + DHAEPA + DHA (mg)Source (4 oz or 114 g serving)**2,400Salmon (Atlantic), herring (Pacific)2,290Herring (Atlantic)2,060Mackerel (Pacific and jack)1,940Salmon (chinook)1,830Whitefish1,710Tuna (bluefin)1,560Oysters (cooked)1,490Salmon (coho, farmed)1,370Mackerel (Atlantic), trout (farmed, rainbow)1,190Pink salmon canned1,110Bass (striped)1,030Trout (mixed species)980Tuna albacore canned870Bass (sea bass, freshwater)540Halibut (Atlantic and Pacific)470King crab340Flounder/sole320Tuna (yellowfin), Cod (Pacific)270Catfish wild220Lobster180Cod (Atlantic)150Tilapia120Shrimp100Catfish (farm)DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.Table 3**Amounts of EPA and DHA in commonly available supplementsBrand/productEPA (mg)DHA (mg)Comment**Cardiotabs omega-3 enteric-coated270705Cardiotabs omega-3 extra strength + vitamin D3400800Cardiotabs ultra strength liquid omega-3 + vitamin D3 (per 5 ml)6101570DSM MEG-3® ethyl ester 1,000 mg capsules420210As ethyl estersGlaxoSmithKline Lovaza™445385As ethyl estersGNC ultra triple strength omega 1560 EPA & DHA719281GNC Now® ultra omega-3500250GNC Natrol® omega-3 fish oil 1,200 mg216144GNC Triple Strength Omega Complex647253GNC Triple Strength Fish Oil 1500540360Kirkland Signature™ omega-3 fish oil410274As ethyl estersNatureMade Fish Oil 1,200 mg180120NatureMade Ultra Omega-3 Fish Oil 1,400 mg683252Nordic Naturals Ultimate Omega D3, 1,000 mg, soft gels, lemon650450Puritan's Pride Triple Omega 3-6-9 fish and flax oils398 to 450255 to 300DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid.

How might EPA and DHA act to prevent breast cancer? Preclinical mechanistic studies {#Sec4}
===================================================================================

Most of the work assessing how EPA and DHA might work to reduce breast cancer risk has been performed in *in vitro* or in transgenic mouse models and is far from conclusive. However, the predominant mechanisms are thought to be: a reduction in proinflammatory eicosanoids and an increase in inflammation-resolving derivatives as detailed previously (Figure [2](#Fig2){ref-type="fig"}); a reduction in oncogenic protein signaling through disruption of plasma membrane lipid rafts; a reduction in cytokine production; and an increase in apoptosis following activation of plasma membrane GRP120 protein receptor, which along with activation of peroxisome proliferator-activated receptor gamma blocks nuclear factor-κB translocation to the nucleus \[[@CR8],[@CR9]\].

EPA and DHA disrupt lipid rafts, sphingolipid/cholesterol-enriched microdomains of plasma membranes that optimize signaling by concentrating proteins. Lipid rafts are particularly important for several tyrosine kinase receptors, and reduction in epidermal growth factor receptor and human epidermal growth factor-2 receptor level and activation has been demonstrated in transformed and malignant cells \[[@CR10]-[@CR12]\]. A decrease in epidermal growth factor receptor and human epidermal growth factor-2 signaling would be expected to reduce proliferation, and a decrease in Ki-67 has indeed been observed in benign and malignant mammary tissue after EPA and DHA supplementation in most preclinical models \[[@CR32]-[@CR35]\].

Nuclear factor-κB nuclear translocation and signaling is reduced via the agonist effects of EPA and DHA on peroxisome proliferator-activated receptor gamma as well as interaction with the G protein receptor GPR120, with expected reduction in inhibitors of apoptosis as well as cytokines, adhesion molecules, and metalloproteases \[[@CR9]\]. Additional preclinical studies suggest that EPA and DHA increase expression of BRCA1/2, phosphatase and tensin homolog (PTEN), and other proteins associated with cell cycle control and DNA repair \[[@CR32],[@CR36],[@CR37]\].

Preclinical models of mammary cancer prevention {#Sec5}
===============================================

Studies in rodent models find that increasing the ratio of total omega-3:omega-6 in feed to \>1 (usually with EPA + DHA between 8 and 25% of calories) reduces mammary cancer incidence and multiplicity by 20 to 35% \[[@CR22],[@CR32],[@CR37]-[@CR41]\]*.* Reductions in tumor incidence have been observed in the estrogen receptor-negative MMTV-HER-2/neu transgenic mice \[[@CR39],[@CR40]\], the estrogen receptor-positive NMU rat model \[[@CR32],[@CR37]\], and the estrogen receptor-positive DMBA rat model \[[@CR41]-[@CR43]\]. The minimum dose of marine omega-3 fatty acids for effect is not clear and may vary by animal model, source of EPA and DHA (fish oil versus ethyl esters), and total amount and type of fat in the diet. Other important experimental conditions include when in an animal's lifespan supplementation is started (younger may be more protective than older), and whether agent is added to feed or administered by gavage as omega-3 fatty acids are readily oxidized once exposed to light \[[@CR38]\]. Several preclinical studies suggest that EPA/DHA supplementation may be most optimal for prevention of estrogen receptor-positive breast cancer when used with another chemoprevention agent such as vitamin D \[[@CR41]\], a selective estrogen receptor modulator \[[@CR43]\], or celecoxib \[[@CR42]\].

Human studies {#Sec6}
=============

Results of case--control and cohort studies have to date been variable, probably reflecting the heterogeneity of cohorts, methods used to assess omega-3 and omega-6 exposure, time from exposure when measures were taken, dose, and response endpoint.

Pharmacodynamics {#Sec7}
----------------

Omega-3 and omega 6 fatty acids are incorporated at different rates in different tissues and tissue components. Levels as a percentage of total fatty acids vary tremendously between tissues/organs although, with supplementation, levels of EPA and DHA rise in a fairly proportional manner \[[@CR44]\]. Substantial increases in monocyte membrane DHA and EPA and decreases in monocyte AA may be seen as early as 1 week after beginning supplementation and do not change dramatically over the ensuing several weeks \[[@CR9],[@CR26]\]. The time to EPA maximum uptake is \~2 weeks in plasma triglycerides, 3 weeks in serum cholesterol esters, \~2 months in red blood cells (RBCs), and \>12 months for most types of adipose tissue. The highest levels of EPA and DHA in the blood are generally in the RBC membranes (RBC phospholipids), plasma phospholipids, and cholesterol esters and platelets, although mononuclear cells also contain appreciable amounts \[[@CR45]\]. The concentration of EPA and DHA in subcutaneous or breast adipose is 1/10 or less of that in the blood compartments \[[@CR44]\]. DHA is generally much higher than EPA in most body organs, including the brain and retina, but its incorporation into RBCs lags behind EPA \[[@CR26],[@CR28],[@CR29],[@CR46]\]. Women generally have higher levels of EPA and DHA than men following equivalent dosing, and older women have higher levels than younger women \[[@CR45]\]. Individuals who take fish oil supplements tend to take them daily whereas consumption of fish may be more intermittent. Browning and colleagues determined in a 12-month study of adults taking identical weekly doses of EPA + DHA that those taking continuous daily doses had higher EPA and DHA levels in monocytes and platelets than those taking intermittent doses \[[@CR47]\].

For clinical trials, chronic exposure is generally assessed by measuring EPA, DHA, and AA RBC phospholipids, although some investigators feel that monocyte or platelet phospholipid measures are superior to those in RBCs \[[@CR29]\].

Case--control studies {#Sec8}
---------------------

Results of case--control studies, particularly when questionnaires are used as the primary measure of exposure, are mixed, probably reflective of the accuracy of recall and food frequency questionnaires in estimating dietary intake. There is no significant association between total fish intake and breast cancer particularly in populations where total fish and fatty fish consumption tends to be low \[[@CR48],[@CR49]\]. EPA and DHA content varies tremendously by type of fish, which may not be well specified in the questionnaires. However, two case--control studies (one from Mexico and another from the United States) using dietary recall instruments suggest breast cancer risk reduction in premenopausal women with higher intakes of omega-3 fatty acids from diet and supplements \[[@CR50],[@CR51]\].

Measurement of the fatty acid composition in blood cell membranes (phospholipids) and adipose is thought to be a good indicator of chronic exposure to omega-3 and omega-6 fatty acids and thus avoids some of the problems with dietary recall. A nested case--control study within a prospective cohort of women in Shanghai China, a population with relatively high fish intake, found that total omega-3 fatty acids and EPA in red cells were associated with significantly lower risk of proliferative breast disease and breast cancer \[[@CR52],[@CR53]\]. Similar findings were reported in a Japanese cohort where total omega-3, EPA, and DHA in red cells was inversely associated with breast cancer risk \[[@CR54]\]. Another case--control study suggested reduced risk of breast cancer with higher ratios of omega-3 to omega-6 in breast adipose \[[@CR55]\]. No association was reported between the risk biomarker mammographic breast density and omega-3 fatty acids \[[@CR56]\].

Prospective cohort studies of omega-3 fatty acids and breast cancer risk {#Sec9}
========================================================================

A meta-analysis of 16 prospective cohort studies examining marine omega-3 intake suggests a reduction in breast cancer risk when individuals with highest intakes are compared with those with lowest intakes of marine PUFA (EPA, docosapentaenoic acid, and DHA) in the diet or the diet plus supplements \[[@CR57]\]. The method for assessment of marine PUFA exposure varied from dietary questionnaire to blood or tissue n-3 PUFA assessment. Overall the relative risk for highest exposure was 0.86 (95% confidence interval, 0.97 to 1.03). The affect appeared strongest for marine PUFA in postmenopausal women but there were fewer premenopausal women studied \[[@CR57]\]. In three of the largest studies -- the Singapore Chinese Health Study \[[@CR58]\], the Japanese Collaborative Cohort Study \[[@CR59]\], and the Vitamins and Lifestyle (VITAL) study from western Washington state \[[@CR60]\] -- there was a significant reduction in relative risk in the individual trials ranging from 31 to 50%. Current use of fish oil supplements (generally 300 mg EPA + DHA or more per capsule) in the VITAL trial in women aged \>50 years was associated with a 32% reduction in risk of breast cancer (hazard ratio, 0.68; 95% confidence interval, 0.50 to 0.92) \[[@CR60],[@CR61]\].

Eight studies were available for dose--response analysis, which showed that a 0.1 g/day increment and/or 0.1% of energy intake increments were associated with a 5% reduction in breast cancer risk \[[@CR57]\]. In this same meta-analysis no association was observed between total fish intake, total PUFA or ALA (the shorter chain omega-3 fatty acid) intake and breast cancer risk \[[@CR57]\].

A recent meta-analysis combined six prospective nested case--control studies and five cohort studies in which the omega-3:omega-6 intake ratio and/or omega-3:omega-6 ratio in serum phospholipids was known. There were over 274,000 women, and more than 8,300 breast cancer events. Their conclusions were that each 1/10 increment in the dietary n-3:n-6 ratio was associated with a 6% reduction in breast cancer risk, and amongst US subjects each 1/10 increment in the serum n-3:n-6 phospholipid ratio was associated with a 27% reduction in breast cancer risk \[[@CR49]\].

Interventional studies for primary prevention of breast cancer {#Sec10}
--------------------------------------------------------------

Although one is not likely to achieve EPA + DHA intake in human trials at the same percentage of calories as in animal prevention trials, doses of EPA and DHA ethyl esters up to \~7 g/day given to healthy women are well tolerated \[[@CR62]\]. A dose of 3.4 g/day DHA + EPA ethyl esters, providing \~ 2% of calories, is US Food and Drug Administration approved for treatment of hypertriglyceridemia. Importantly, this dose should produce an EPA + DHA:AA ratio approaching equivalence and thus provide an anti-inflammatory effect.

Human studies in healthy individuals show little effect of marine PUFA on blood inflammatory biomarkers, although a recent randomized trial in healthy young adults given 0, 300, 600, 900, or 1,800 mg/day EPA + DHA for 5 months showed a marginal decrease in serum tumor necrosis factor alpha (*P* = 0.08) but no change in interleukin-6 \[[@CR63]\].

Human studies in inflammatory disorders show little evidence of a systemic anti-inflammatory effect such as reduction of cytokines or prostaglandin E~2~ levels with doses of combined EPA + DHA less than \~3.5 g/day and/or EPA-alone doses \<2.7 g/day \[[@CR26],[@CR64]\]. However, experts in this area suggest that systemic measures of cytokines in inflammatory conditions are likely to be insensitive compared with measuring conditions in the tissue of interest \[[@CR65]\].

Signori and colleagues are conducting a trial of raloxifene 30 mg, raloxifene 60 mg, Lovaza™ (GlaxoSmithKline) 4 g, Lovaza™ 4 g + raloxifene 30 mg, or no intervention in postmenopausal women with \>25% breast density. No change with Lovaza™ has been found in the first 46 women in secondary endpoint blood risk biomarkers such as insulin-like growth factor I and insulin-like growth factor-binding protein 3 or the inflammatory marker high-sensitivity C-reactive protein \[[@CR66]\].

We have completed separate pilot studies of 3.4 g/day EPA + DHA ethyl esters (4 g Lovaza™) administered for 6 months to explore effects on benign breast tissue risk biomarkers for breast cancer in premenopausal and postmenopausal women at increased risk for breast cancer. Favorable modulation of several tissue risk biomarkers for breast cancer was observed \[[@CR67],[@CR68]\].

A study of particular interest is the ongoing VITAL trial (NCT01169259) which aims to randomize over 28,000 men and women to vitamin D3 (2,000 IU/day), omega-3 fatty acids (840 mg EPA + DHA), both, or none, with a primary outcome of reduction in risk for cancer, stroke, and other diseases. Eligible women must be age 55 years and over.

Omega-3 fatty acids and breast cancer survivorship {#Sec11}
==================================================

There is also interest in EPA and DHA for improvement of outcomes after a diagnosis of breast cancer. Breast cancer recurrence, cardiovascular events, weight gain and obesity, bone density loss, and chemotherapy-associated cognitive impairment and peripheral neuropathy are common concerns during the survivorship period. Although there is little in the way of definitive interventional trials, we will review here some of the more interesting preliminary results.

EPA and DHA and reduction of breast cancer recurrence {#Sec12}
-----------------------------------------------------

Higher intakes of EPA and DHA from dietary sources were reported to be associated with a 25% reduction in breast cancer recurrence and improved overall mortality in a large cohort of over 3,000 women with early stage breast cancer followed for a median of 7 years \[[@CR69]\]. One reason for this observation may be enhancement of at least some types of chemotherapeutic cytotoxicity, which has been reported for concomitant administration of DHA with anthracyclines \[[@CR70],[@CR71]\]. This enhanced cytotoxicity probably results from alteration in membrane lipid rafts, which increases surface expression and clustering of the death receptor CD95 in mammary cancer cell lines treated with EPA and DHA and doxorubicin \[[@CR72]\]. Improved outcome with DHA added to chemotherapy in a small phase II trial has been reported in metastatic breast cancer patients \[[@CR73]\]. This observation raises the question of whether cardiac toxicity might also be increased by adding EPA or DHA to anthracyclines, but this does not appear to be the case at least in rats \[[@CR74]\].

EPA and DHA to reduce cardiac events {#Sec13}
------------------------------------

Cardiac events are the second most common cause of mortality in women with breast cancer, and the most common cause of death for women with stage I breast cancer over the age of 65. EPA and DHA reduce triglycerides and platelet aggregation and are thought to have an anti-arrhythmic effect. EPA and DHA supplementation have been noted to be associated with reduced cardiac deaths in the general population \[[@CR75],[@CR76]\]. A highly purified prescription strength form of \~3.4 g/day EPA and DHA (Lovaza™, formerly omacor, 4 g/day) is US Food and Drug Administration approved for treatment of hypertriglyceridemia and has been shown to reduce triglycerides and nonhigh-density lipoproteins to a greater extent than a statin alone in individuals with mixed dyslipidemia and triglycerides \>200 mg/dl \[[@CR77]\]. This highly purified prescription formulation has also been shown to reduce cardiac events and mortality in individuals with a prior myocardial infarction at lower doses of 1 g/day \[[@CR77]\]. However, a recent secondary prevention trial with 1 g/day EPA and DHA compared with 1 g/day olive oil did not show any cardioprotective effect \[[@CR78]\]. A recent meta-analysis of EPA and DHA in moderate doses also showed no benefit \[[@CR79]\]. The cause of these discrepancies is open to speculation. Possibilities include the following: 1) a lack of additional benefit for EPA + DHA in women with cardiac disease already on optimal medical management; 2) the placebo, often olive oil, may also have cardiovascular benefit; 3) or the highly purified forms of EPA + DHA may have special properties such as lower reactive oxygen species than less purified forms of fish oil \[[@CR80]\]. Trials such as the VITAL trial in women without a prior history of heart disease will be of great interest.

EPA and DHA to reduce bone density loss and arthralgias {#Sec14}
-------------------------------------------------------

Loss of bone density and increased fracture rate are a side effect of premature menopause caused by cytotoxic chemotherapy or surgical ovarian ablation in premenopausal women or use of aromatase inhibitors in postmenopausal women. EPA and DHA probably inhibit RANK ligand and osteoclast formation \[[@CR81]\]. A small randomized pilot trial suggests that 3 g/day EPA and DHA inhibits bone reabsorption in individuals taking aromatase inhibitors \[[@CR82]\]. The anti-inflammatory activity and beneficial effects of EPA and DHA on rheumatoid arthritis have led to a clinical trial of high-dose EPA and DHA versus placebo in women who have aromatase inhibitor-induced arthralgias. This cooperative group study of 262 women has been reported in abstract form and no benefit was observed \[[@CR83]\]. A small randomized trial of omega-3 fatty acids to protect against taxane-induced neuropathy suggests benefit \[[@CR84]\] and further studies are needed.

EPA and DHA to prevent insulin resistance and sarcopenic weight gain {#Sec15}
--------------------------------------------------------------------

EPA and DHA help prevent obesity and insulin resistance particularly in animal models fed a high-fat diet \[[@CR85],[@CR86]\], but effects in humans have yet to be proven. Sarcopenic weight gain is common during adjuvant chemotherapy for breast cancer. The anabolic effects of EPA and DHA might help reduce muscle mass loss and weight gain during treatment and weight gain following diagnosis, but studies in this area have yet to be conducted \[[@CR87],[@CR88]\]. Results of the Muscle Mass, Omega-3, Diet, Exercise and Lifestyle (MODEL) trial in healthy individuals aged \>70 years examining the effects of 90 minutes of exercise weekly, vitamin D3 (2,000 IU/day) or 1 g EPA and DHA daily are awaited with interest \[[@CR89]\].

EPA and DHA and cognition {#Sec16}
-------------------------

Cognitive abnormalities are observed in 20 to 70% of women after chemotherapy depending on the agents used, intensity and duration of treatment, predisposing factors, and type and scoring of cognitive tests \[[@CR90],[@CR91]\]. DHA is the most abundant PUFA in the brain and is involved in multiple functions including cell signaling, neurogenesis, neuroprotection, and learning and memory \[[@CR18]\]. A number of epidemiologic studies show a 40 to 50% reduction in risk of multicause dementia with increased dietary intake of DHA or increased blood levels of DHA \[[@CR19]\]. In meta-analyses, DHA supplementation improves attention, processing speed and immediate recall, learning, and memory in individuals with cognitive impairment without dementia but not in those with dementia \[[@CR92],[@CR93]\]. Probable mechanisms include suppression of oxidative stress \[[@CR94]\], decreases in proinflammatory lipid derivatives from AA, an increase in inflammation resolving and protective lipid derivatives, enhanced production of neurotransmitters \[[@CR95]\], and reduced production and accumulation of amyloid B peptide toxin \[[@CR19]\]. Doses of DHA administered as supplements for cognitive improvement are generally in the range of 1,800 mg/day. Studies utilizing DHA or DHA + EPA as a neuroprotectant during chemotherapy are needed.

Conclusion {#Sec17}
==========

The inflammation-resolving properties and favorable effects of EPA and DHA on oncogenic proteins, as well as on the cardiovascular, bone, and central nervous system, make them excellent candidates for primary and secondary breast cancer prevention trials for individuals at increased risk as well as breast cancer survivors. Interventional trials in these cohorts are ongoing.
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